Laboratories are the Forgotten Stakeholder in Personalized Medicine | Diaceutics

Laboratories are the Forgotten Stakeholder in Personalized Medicine

January 10th, 2013

Mark Reis

Mark Reis highlights the importance of the laboratory in the delivery of personalized medicine and explains how the Diaceutics network adds value by creating a halo effect for both the laboratory and the therapy.

[Note, July 2017: Labceutics is now known as Diaceutics]

Laboratories are often the forgotten partners in the delivery of personalized therapies to physicians worldwide, yet the research and quality of their service in delivering seamless test results to physicians can either enhance the value proposition of a targeted therapy or destroy it. The need for integrated highest quality laboratory networks in fragmented markets such as Europe and Asia are required to truly leverage the power of companion diagnostics. Our research shows that a well-designed superior laboratory service translates into a higher return on investment for targeted therapy teams. The research and experience Labceutics has in the marketplace clearly demonstrates that therapy teams seeking to improve the doctor-laboratory dynamic and facilitate use and interpretation of a particular targeted therapeutic should be engaging with laboratories that specialize in providing ‘gold-plated’ services to doctors. The Labceutics network provides a higher level of service to the point that it actually adds value to the treatment, creating a halo effect for both the laboratory and the therapy.

The quality and value of laboratory information depends on an array of factors, including selecting the right test at the right time for the right patient. There can be a significant difference in laboratory use among physicians investigating patients with the same diagnosis and also a significant number of tests that are ordered unnecessarily. Even if doctors believe a test is relevant, they may hesitate to requisition it if the order process is unwieldy or the form is confusing. Conversely, reports that are difficult to read or interpret, or that present ambiguous results, may deter physicians from reordering a test. Physicians may choose to order a test from a different laboratory, or not to order it at all. As guidelines do not necessarily specify the preferred testing method (kit or LDT), pathologists are typically responsible and trusted by physicians to determine the right method of testing, which can cause a level of confusion. Grouped together, these challenges conspire to negatively impact appropriate test adoption.

Labceutics allows pharmaceutical companies to communicate directly with laboratories that are working directly with the prescribing doctors. The quality and access of available testing is optimized for the specific personalized medicine drug launch and fully integrates into the drug brand. Labceutics ‘personalized medicine-ready footprint’ enables rapid market access, transparency and clinical services that result in significantly improved test turnaround times, resource savings and improved outcomes. Whether an LDT or in vitro diagnostic, Labceutics covers all the bases to ensure the highest testing quality, standards and delivery.

The full article and research can be found here: [php snippet=34 param=”id=89″].

 

Blogs

View all blogs

Webinars & Podcasts

July 5th, 2019
Liquid Biopsy in NSCLC
August 9th, 2018
Podcast: Oncology Patient Research
Why do we need to talk biomarkers with patients? Senior Director of Market Research at Diaceutics, Marianne Fillion, recently spearheaded an effort to gather insights directly from oncology patients to get an understanding of what they know about ...
View all

Expert Insights

April 19th, 2018
The CMS National Coverage Decision on NGS
I. Introduction On March 16, 2018, the Centers for Medicare and Medicaid Services (CMS) finalized a National Coverage Determination (NCD) that cove...
January 19th, 2018
What does the EU IVD Regulation mean for companion diagnostics and LDTs?
Dave Smart, PhD, Director at Diaceutics, discusses the introduction of the EU IVD Regulation. While it is considered a necessary step, the Regulati...
View all expert insights

Competitive Benchmarking Reports

March 16th, 2018
PM Readiness Report 2018 Summary
March 14th, 2017
Pharma Readiness for Diagnostic Integration 2017
View all reports

Case Studies

View all case studies

Publications

June 25th, 2019
FLT3 testing in relapsed Acute Myeloid Leukemia setting is becoming increasingly common, but laboratory turnaround times (TAT) may be a barrier to treatment with second generation FLT3 inhibitors
The treatment landscape in AML has developed at an astonishing pace in the last 3 years, with 5 therapies being approved by the FDA. FLT3 inhibitors gilteritinib (Gil) and quizartinib (Quiz) present an unprecedented opportunity for improved surviv...
May 23rd, 2019
Diaceutics reviews the ongoing debate on diagnostics reform legislation
Thought leaders at Diaceutics recently authored a peer-reviewed article that covers the ongoing national debate over diagnostics reform legislation in the United States. The article is now available online ahead of print in the Journal of Molecula...
View all publications